RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.

Also called NCT03064126

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 440 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03064126
Other papers using this trial's data
  • 1-Year Results From the RANGER II SFA Randomized Trial of the Ranger Drug-Coated Balloon JACC. Cardiovascular interventions, 2021-05-24 DOI, PubMed 34016410
  • One-year results for Japanese patients in RANGER II SFA Heart and vessels, 2022-04 DOI, PubMed 34557931

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Belgium, Canada, Japan, New Zealand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03064126. Randomized; single masking; primary purpose treatment. Start 2017-03-02 (actual); primary completion 2019-11-18 (actual). Results posted on 2020-07-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
Acronym
RANGER II SFA
Condition
Peripheral Artery Disease
Condition
Atherosclerosis
Condition
Artery Diseases, Peripheral
Condition
Plaque, Atherosclerotic
Condition
Occlusive Arterial Disease
Intervention (Device)
RANGER™ Paclitaxel Coated Balloon
Intervention (Drug)
Paclitaxel
Intervention (Procedure)
Standard Balloon Angioplasty
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct03064126
Content hash
66a6f66964dc84b33673843e569a19d7d4953f657850e359cf91815dd867a23d